Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond
2015; Elsevier BV; Volume: 43; Issue: 8 Linguagem: Inglês
10.1016/j.exphem.2015.05.012
ISSN1873-2399
AutoresChun‐Wei Chen, Scott A. Armstrong,
Tópico(s)Genomics and Chromatin Dynamics
Resumo•The histone methyltransferase DOT1L is required for proliferation of mixed-lineage leukemia gene (MLL)-rearranged leukemias.•DOT1L and H3K79 methylation maintains high-level HOXA and MEIS 1 gene expression.•DOT1L inhibition induces differentiation of MLL-rearranged and other high-level HOXA leukemias.•DOT1L inhibitors are in clinical trials. Leukemias harboring mixed-lineage leukemia gene (MLL1) abnormalities are associated with poor clinical outcomes, and new therapeutic approaches are desperately needed. Rearrangement of the MLL1 gene generates chimeric proteins that fuse the NH3 terminus of MLL1 to the COOH terminus of its translocation partners. These MLL1 fusion oncoproteins drive the expression of homeobox genes such as HOXA cluster genes and myeloid ecotropic viral integration site 1 homolog (MEIS1), which are known to induce leukemic transformation of hematopoietic progenitors. Genomewide histone methylation studies have revealed that the abnormal expression of MLL1 fusion target genes is associated with high levels of H3K79 methylation at these gene loci. The only known enzyme that catalyzes methylation of H3K79 is disruptor of telomeric-silencing 1-like (DOT1L). Loss-of-function mouse models, as well as small molecular inhibitors of DOT1L, illustrate that leukemias driven by MLL1 translocations are dependent on DOT1L enzymatic activity for proliferation and for the maintenance of HOXA gene expression. Furthermore, DOT1L also appears to be important for HOXA gene expression in other settings including leukemias with select genetic abnormalities. These discoveries have established a foundation for disease-specific therapies that target chromatin modifications in highly malignant leukemias harboring specific genetic abnormalities. This review focuses on the molecular mechanisms underlying MLL1 translocation-driven leukemogenesis and the latest progress on DOT1L-targeted epigenetic therapies for MLL1-rearranged and other leukemias. Leukemias harboring mixed-lineage leukemia gene (MLL1) abnormalities are associated with poor clinical outcomes, and new therapeutic approaches are desperately needed. Rearrangement of the MLL1 gene generates chimeric proteins that fuse the NH3 terminus of MLL1 to the COOH terminus of its translocation partners. These MLL1 fusion oncoproteins drive the expression of homeobox genes such as HOXA cluster genes and myeloid ecotropic viral integration site 1 homolog (MEIS1), which are known to induce leukemic transformation of hematopoietic progenitors. Genomewide histone methylation studies have revealed that the abnormal expression of MLL1 fusion target genes is associated with high levels of H3K79 methylation at these gene loci. The only known enzyme that catalyzes methylation of H3K79 is disruptor of telomeric-silencing 1-like (DOT1L). Loss-of-function mouse models, as well as small molecular inhibitors of DOT1L, illustrate that leukemias driven by MLL1 translocations are dependent on DOT1L enzymatic activity for proliferation and for the maintenance of HOXA gene expression. Furthermore, DOT1L also appears to be important for HOXA gene expression in other settings including leukemias with select genetic abnormalities. These discoveries have established a foundation for disease-specific therapies that target chromatin modifications in highly malignant leukemias harboring specific genetic abnormalities. This review focuses on the molecular mechanisms underlying MLL1 translocation-driven leukemogenesis and the latest progress on DOT1L-targeted epigenetic therapies for MLL1-rearranged and other leukemias. It has been recognized for more than 30 years that 11q23 chromosomal translocations are found in both acute lymphoid leukemias (ALLs) and acute myeloid leukemias (AMLs) [1Morse H.G. Heideman R. Hays T. Robinson A. 4;11 translocation in acute lymphoblastic leukemia: a specific syndrome.Cancer Genet Cytogenet. 1982; 7: 165-172Abstract Full Text PDF PubMed Scopus (15) Google Scholar, 2Prigogina E.L. Fleischman E.W. Puchkova G.P. et al.Chromosomes in acute leukemia.Hum Genet. 1979; 53: 5-16Crossref PubMed Scopus (80) Google Scholar, 3Van den Berghe H. David G. Broeckaert-Van Orshoven A. et al.A new chromosome anomaly in acute lymphoblastic leukemia (ALL).Hum Genet. 1979; 46: 173-180Crossref PubMed Scopus (67) Google Scholar, 4Mirro J. Kitchingman G. Williams D. et al.Clinical and laboratory characteristics of acute leukemia with the 4;11 translocation.Blood. 1986; 67: 689-697PubMed Google Scholar]. In many cases, a mixture of cell surface markers of lymphoid and myeloid lineages can be found on leukemia cells, or a phenotypic lineage switch (e.g., initially diagnosed ALL could relapse as AML) is observed in patients with leukemias harboring 11q23 translocations [5Mirro J. Zipf T.F. Pui C.H. et al.Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance.Blood. 1985; 66: 1115-1123PubMed Google Scholar, 6Stass S. Mirro J. Unexpected heterogeneity in acute leukemia: mixed lineages and lineage switch.Hum Pathol. 1985; 16: 864-866Abstract Full Text PDF PubMed Google Scholar]. The presence of 11q23 translocations led to the cloning of a critical gene that resides on 11q23 known as the mixed-lineage leukemia gene (MLL1, also known as MLL, ALL-1, HRX, and TRX1) [7Djabali M. Selleri L. Parry P. Bower M. Young B.D. Evans G.A. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias.Nat Genet. 1992; 2: 113-118Crossref PubMed Google Scholar, 8Gu Y. Nakamura T. Alder H. et al.The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.Cell. 1992; 71: 701-708Abstract Full Text PDF PubMed Scopus (577) Google Scholar, 9Tkachuk D.C. Kohler S. Cleary M.L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias.Cell. 1992; 71: 691-700Abstract Full Text PDF PubMed Scopus (624) Google Scholar, 10Ziemin-van der Poel S. McCabe N.R. Gill H.J. et al.Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.Proc Natl Acad Sci U S A. 1991; 88: 10735-10739Crossref PubMed Google Scholar]. Rearrangement of MLL1 is found in approximately 5% of ALL cases and around 5% to 10% of AML cases in adults [11Armstrong S.A. Look A.T. Molecular genetics of acute lymphoblastic leukemia.J Clin Oncol. 2005; 23: 6306-6315Crossref PubMed Scopus (187) Google Scholar, 12Huret J.L. Dessen P. Bernheim A. Groupe Français de Cytogénétique OncologiqueAn atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners.Leukemia. 2001; 15: 987-989Crossref PubMed Scopus (72) Google Scholar, 13Krivtsov A.V. Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development.Nat Rev Cancer. 2007; 7: 823-833Crossref PubMed Scopus (430) Google Scholar, 14Meyer C. Kowarz E. Hofmann J. et al.Oncogenes, fusion genes and tumor suppressor genes: new insights to the MLL recombinome of acute leukemias.Leukemia. 2009; 23: 1490-1499Crossref PubMed Scopus (202) Google Scholar, 15Meyer C. Schneider B. Jakob S. et al.The MLL recombinome of acute leukemias.Leukemia. 2006; 20: 777-784Crossref PubMed Scopus (133) Google Scholar]. MLL1 rearrangements are frequently found in leukemias of childhood, particularly in infant (<1 year old) leukemias, whether they are diagnosed as AML or ALL [16Raimondi S.C. Chang M.N. Ravindranath Y. et al.Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study—POG 8821.Blood. 1999; 94: 3707-3716PubMed Google Scholar]. MLL1 translocations are detected in more than 70% of infant ALL cases and about 35%–50% of infant AML patients [17Mohan M. Lin C. Guest E. Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis.Nat Rev Cancer. 2010; 10: 721-728Crossref PubMed Scopus (63) Google Scholar, 18Chessells J.M. Harrison C.J. Kempski H. et al.Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.Leukemia. 2002; 16: 776-784Crossref PubMed Scopus (50) Google Scholar, 19Hilden J.M. Dinndorf P.A. Meerbaum S.O. et al.Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.Blood. 2006; 108: 441-451Crossref PubMed Scopus (105) Google Scholar, 20Pieters R. Schrappe M. De Lorenzo P. et al.A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.Lancet. 2007; 370: 240-250Abstract Full Text Full Text PDF PubMed Scopus (216) Google Scholar, 21Tomizawa D. Koh K. Sato T. et al.Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group.Leukemia. 2007; 21: 2258-2263Crossref PubMed Scopus (39) Google Scholar, 22Van der Linden M.H. Valsecchi M.G. De Lorenzo P. et al.Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.Blood. 2009; 114: 3764-3768Crossref PubMed Scopus (23) Google Scholar, 23Biondi A. Cimino G. Pieters R. Pui C.H. Biological and therapeutic aspects of infant leukemia.Blood. 2000; 96: 24-33PubMed Google Scholar, 24Huret J.L. Dessen P. Le Minor S. Bernheim A. The "Atlas of genetics and cytogenetics in oncology and haematology" on the Internet and a review on infant leukemias.Cancer Genet Cytogenet. 2000; 120: 155-159Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar]. In addition, MLL1 translocation is found in therapy-related leukemias that develop in patients previously treated with topoisomerase II inhibitors [25Felix C.A. Hosler M.R. Winick N. Masterson M. Wilson A.E. Lange B.J. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.Blood. 1995; 85: 3250-3256Crossref PubMed Google Scholar, 26Felix C.A. Secondary leukemias induced by topoisomerase-targeted drugs.Biochim Biophys Acta. 1998; 1400: 233-255Crossref PubMed Scopus (294) Google Scholar, 27Pui C.H. Relling M.V. Topoisomerase II inhibitor-related acute myeloid leukaemia.Br J Haematol. 2000; 109: 13-23Crossref PubMed Google Scholar, 28Meyer C. Hofmann J. Burmeister T. et al.The MLL recombinome of acute leukemias in 2013.Leukemia. 2013; 27: 2165-2176Crossref PubMed Scopus (62) Google Scholar, 29Schoch C. Schnittger S. Klaus M. Kern W. Hiddemann W. Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: Incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.Blood. 2003; 102: 2395-2402Crossref PubMed Scopus (174) Google Scholar]. Although a recent genome-scale sequencing project revealed that MLL1-rearranged leukemias harbor relatively low frequencies of somatic mutations compared with other types of cancer [30Andersson A.K. Ma J. Wang J. et al.The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.Nat Genet. 2015; 47: 330-337Crossref PubMed Scopus (3) Google Scholar], patients with 11q23 rearrangements generally have a poor prognosis and are treated according to high-risk protocols. The 5-year survival rate of infant ALL patients with MLL1 rearrangements (15%–50%) is significantly lower than that of infant ALL patients without MLL1 abnormalities (event-free survival: 70%–80%) [19Hilden J.M. Dinndorf P.A. Meerbaum S.O. et al.Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.Blood. 2006; 108: 441-451Crossref PubMed Scopus (105) Google Scholar, 21Tomizawa D. Koh K. Sato T. et al.Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group.Leukemia. 2007; 21: 2258-2263Crossref PubMed Scopus (39) Google Scholar, 31Chen C.S. Sorensen P.H.B. Domer P.H. et al.Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome.Blood. 1993; 81: 2386-2393Crossref PubMed Google Scholar, 32Pui C.H. Sandlund J.T. Pei D. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.Blood. 2004; 104: 2690-2696Crossref PubMed Scopus (260) Google Scholar]. The survival rate of infants with leukemias with MLL1 translocations remains low (approximately 50%, with worse outcome for the youngest patients), even with intensive chemotherapies and allogeneic hematopoietic stem cell transplantation [33Kosaka Y. Koh K. Kinukawa N. et al.Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation.Blood. 2004; 104: 3527-3534Crossref PubMed Scopus (60) Google Scholar, 34Mann G. Attarbaschi A. Schrappe M. et al.Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study.Blood. 2010; 116: 2644-2650Crossref PubMed Scopus (30) Google Scholar, 35Muntean A.G. Hess J.L. The pathogenesis of mixed-lineage leukemia.Annu Rev Pathol. 2012; 7: 283-301Crossref PubMed Scopus (66) Google Scholar]. The World Health Organization (WHO) classifies myeloid leukemias with 11q23 abnormalities as one group, with an estimated 4-year event-free survival of 24% to 55% [16Raimondi S.C. Chang M.N. Ravindranath Y. et al.Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study—POG 8821.Blood. 1999; 94: 3707-3716PubMed Google Scholar, 18Chessells J.M. Harrison C.J. Kempski H. et al.Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party.Leukemia. 2002; 16: 776-784Crossref PubMed Scopus (50) Google Scholar, 36Stark B. Jeison M. Gabay L.G. et al.Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel.Br J Haematol. 2004; 126: 320-337Crossref PubMed Scopus (24) Google Scholar]. The unmet clinical problem presented by MLL1-rearranged leukemias emphasizes the need for novel therapeutic strategies targeting these difficult-to-treat hematopoietic malignancies. Wild-type MLL1 is a mammalian homologue of Drosophila trithorax and yeast Set1, the first H3K4 methyltransferase identified in Saccharomyces cerevisiae in the early 2000s [37Krogan N.J. Dover J. Khorrami S. et al.COMPASS, a histone H3 (Lysine 4) methyltransferase required for telomeric silencing of gene expression.J Biol Chem. 2002; 277: 10753-10755Crossref PubMed Scopus (217) Google Scholar, 38Miller T. Krogan N.J. Dover J. et al.COMPASS: A complex of proteins associated with a trithorax-related SET domain protein.Proc Natl Acad Sci U S A. 2001; 98: 12902-12907Crossref PubMed Scopus (280) Google Scholar, 39Roguev A. Schaft D. Shevchenko A. et al.The Saccharomyces cerevisiae Set1 complex includes an Ash2 homologue and methylates histone 3 lysine 4.EMBO J. 2001; 20: 7137-7148Crossref PubMed Scopus (152) Google Scholar]. Structurally, the MLL1 protein (3,972 amino acids) contains three AT-hook DNA binding domains at its N-terminal region [40Zeleznik-Le N.J. Harden A.M. Rowley J.D. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene.Proc Natl Acad Sci U S A. 1994; 91: 10610-10614Crossref PubMed Scopus (176) Google Scholar], two speckled nuclear localization motifs (SNL1 and SNL2), a CxxC zinc-finger motif that binds unmethylated CpG-containing DNA [41Birke M. Schreiner S. Garcia-Cuéllar M.P. Mahr K. Titgemeyer F. Stany R.K. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.Nucleic Acids Res. 2002; 30: 958-965Crossref PubMed Google Scholar], four plant homology domains (PHDs) [42Fair K. Anderson M. Bulanova E. Mi H. Tropschug M. Diaz M.O. Protein interactions of the MLL PHD fingers modulate MLL target gene regulation in human cells.Mol Cell Biol. 2001; 21: 3589-3597Crossref PubMed Scopus (84) Google Scholar], a bromodomain, a transcription activation (TA) domain that recruits CREB-binding protein (CBP), and a SET (Su(var)3-9, enhancer of zeste, trithorax) domain located at the extreme C-terminus that contains the H3K4 methyltransferase activity (Fig. 1A) [13Krivtsov A.V. Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development.Nat Rev Cancer. 2007; 7: 823-833Crossref PubMed Scopus (430) Google Scholar, 43Briggs S.D. Bryk M. Strahl B.D. et al.Histone H3 lysine 4 methylation is mediated by Set1 and required for cell growth and rDNA silencing in Saccharomyces cerevisiae.Genes Dev. 2001; 15: 3286-3295Crossref PubMed Scopus (359) Google Scholar, 44Milne T.A. Briggs S.D. Brock H.W. et al.MLL targets SET domain methyltransferase activity to Hox gene promoters.Mol Cell. 2002; 10: 1107-1117Abstract Full Text Full Text PDF PubMed Scopus (583) Google Scholar]. The full-length MLL1 protein is cleaved into MLL1-N (320 kDa) and MLL1-C (180 kDa) fragments by taspase 1 and reassembled to form a stable dimer through the F/Y-rich N terminal (FYRN) and F/Y-rich C terminal (FYRC) domains [45Hsieh J.J. Ernst P. Erdjument-Bromage H. Tempst P. Korsmeyer S.J. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization.Mol Cell Biol. 2003; 23: 186-194Crossref PubMed Scopus (130) Google Scholar, 46Yokoyama A. Kitabayashi I. Ayton P.M. Cleary M.L. Ohki M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties.Blood. 2002; 100: 3710-3718Crossref PubMed Scopus (94) Google Scholar]. The binding of MLL1 to chromatin is associated with transcriptionally active genes [47Milne T.A. Dou Y. Martin M.E. Brock H.W. Roeder R.G. Hess J.L. MLL associates specifically with a subset of transcriptionally active target genes.Proc Natl Acad Sci U S A. 2005; 102: 14765-14770Crossref PubMed Scopus (0) Google Scholar]. Studies revealed that MLL1 (now officially known as lysine-specific methyltransferase 2A or KMT2A) is a histone H3K4 methyltransferase that is part of a protein complex, which is involved in transcriptional regulation [48Nakamura T. Mon T. Tada S. et al.ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation.Mol Cell. 2002; 10: 1119-1128Abstract Full Text Full Text PDF PubMed Scopus (453) Google Scholar]. The MLL1 complex consists of multiple members, some of which are shared among all related MLL complexes (MLL1-4) and some of which are unique to a subset. The components that are shared include WDR5, RBBP5, hDPY30, and ASH2L, all of which interact with the C-terminal region of MLL1. The unique members include multiple endocrine neoplasia I (MENIN) and host cell factor C1 (HCF1), both of which bind to the N-terminal region of MLL1 (Fig. 1B) [49Couture J.F. Collazo E. Trievel R.C. Molecular recognition of histone H3 by the WD40 protein WDR5.Nat Struct Mol Biol. 2006; 13: 698-703Crossref PubMed Scopus (124) Google Scholar, 50Dou Y. Milne T.A. Ruthenburg A.J. et al.Regulation of MLL1 H3K4 methyltransferase activity by its core components.Nat Struct Mol Biol. 2006; 13: 713-719Crossref PubMed Scopus (277) Google Scholar, 51Steward M.M. Lee J.S. O'Donovan A. Wyatt M. Bernstein B.E. Shilatifard A. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes.Nat Struct Mol Biol. 2006; 13: 852-854Crossref PubMed Scopus (162) Google Scholar, 52Crawford B.D. Hess J.L. MLL core components give the green light to histone methylation.ACS Chem Biol. 2006; 1: 495-498Crossref PubMed Scopus (21) Google Scholar, 53Zhang P. Chaturvedi C.P. Tremblay V. et al.A phosphorylation switch on RbBP5 regulates histone H3 Lys4 methylation.Genes Dev. 2015; 29: 123-128Crossref PubMed Google Scholar, 54Shinsky S.A. Monteith K.E. Viggiano S. Cosgrove M.S. Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation.J Biol Chem. 2015; 290: 6361-6375Crossref PubMed Google Scholar, 55Shinsky S.A. Hu M. Vought V.E. et al.A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.J Mol Biol. 2014; 426: 2283-2299Crossref PubMed Scopus (5) Google Scholar, 56Patel A. Vought V.E. Swatkoski S. et al.Automethylation activities within the mixed lineage leukemia-1 (MLL1) core complex reveal evidence supporting a "two-active site" model for multiple histone H3 lysine 4 methylation.J Biol Chem. 2014; 289: 868-884Crossref PubMed Scopus (6) Google Scholar, 57Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.Annu Rev Biochem. 2012; 81: 65-95Crossref PubMed Scopus (138) Google Scholar]. Analysis of H3K4 methylation in MLL1−/− mouse embryonic fibroblasts, which indirectly defines the MLL1 genomic targets, points to approximately 1.8% of genes (299 of 16,327 promoter loci assessed) that are dependent on MLL1 for recruiting RNA polymerase II-mediated transcriptional initiation [58Wang P. Lin C. Smith E.R. et al.Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II.Mol Cell Biol. 2009; 29: 6074-6085Crossref PubMed Scopus (134) Google Scholar]. A hallmark of MLL1-rearranged leukemia is high expression of the homeobox (HOX)-A (HOXA) cluster genes [59Armstrong S.A. Staunton J.E. Silverman L.B. et al.MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.Nat Genet. 2002; 30: 41-47Crossref PubMed Scopus (1075) Google Scholar, 60Dorrance A.M. Liu S. Yuan W. et al.Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.J Clin Invest. 2006; 116: 2707-2716Crossref PubMed Scopus (67) Google Scholar, 61Milne T.A. Martin M.E. Brock H.W. Stany R.K. Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.Cancer Res. 2005; 65: 11367-11374Crossref PubMed Scopus (89) Google Scholar, 62Ferrando A.A. Armstrong S.A. Neuberg D.S. et al.Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.Blood. 2003; 102: 262-268Crossref PubMed Scopus (200) Google Scholar, 63Yeoh E.J. Ross M.E. Shurtleff S.A. et al.Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.Cancer Cell. 2002; 1: 133-143Abstract Full Text Full Text PDF PubMed Scopus (1239) Google Scholar, 64Ross M.E. Zhou X. Song G. et al.Classification of pediatric acute lymphoblastic leukemia by gene expression profiling.Blood. 2003; 102: 2951-2959Crossref PubMed Scopus (364) Google Scholar, 65Kawagoe H. Humphries R.K. Blair A. Sutherland H.J. Hogge D.E. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.Leukemia. 1999; 13: 687-698Crossref PubMed Google Scholar, 66Abramovich C. Humphries R.K. Hox regulation of normal and leukemic hematopoietic stem cells.Curr Opin Hematol. 2005; 12: 210-216Crossref PubMed Scopus (95) Google Scholar]. The HOX gene family is a highly conserved group of homeodomain-containing transcription factors that specify cell identity during organismal development, including body patterning and hematopoiesis [67Alharbi R.A. Pettengell R. Pandha H.S. Morgan R. The role of HOX genes in normal hematopoiesis and acute leukemia.Leukemia. 2013; 27: 1000-1008Crossref PubMed Scopus (28) Google Scholar]. In normal hematopoietic stem and progenitor cells, the expression of developmentally important HOX cluster genes is regulated by MLL1 [65Kawagoe H. Humphries R.K. Blair A. Sutherland H.J. Hogge D.E. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells.Leukemia. 1999; 13: 687-698Crossref PubMed Google Scholar]. Mice that lack MLL1 die during embryonic development and have altered Hox gene expression [68Yu B.D. Hess J.L. Horning S.E. Brown G.A. Korsmeyer S.J. Altered Hox expression and segmental identity in Mll-mutant mice.Nature. 1995; 378: 505-508Crossref PubMed Google Scholar]. These MLL1-null embryos exhibit defects in yolk sac hematopoiesis, with reduced proliferation and/or survival of hematopoietic progenitors [69Hess J.L. Yu B.D. Li B. Hanson R. Korsmeyer S.J. Defects in yolk sac hematopoiesis in Mll-null embryos.Blood. 1997; 90: 1799-1806Crossref PubMed Google Scholar, 70Yagi H. Deguchi K. Aono A. Tani Y. Kishimoto T. Komori T. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice.Blood. 1998; 92: 108-117Crossref PubMed Google Scholar] and defective hematopoietic stem cell activity in the aorta–gonad–mesonephros region [71Ernst P. Fisher J.K. Avery W. Wade S. Foy D. Korsmeyer S.J. Definitive hematopoiesis requires the mixed-lineage leukemia gene.Dev Cell. 2004; 6: 437-443Abstract Full Text Full Text PDF PubMed Scopus (136) Google Scholar]. Mechanistically, MLL1 and its complex partner MENIN bind to genomic DNA at HOX loci and modulate HOX gene expression [44Milne T.A. Briggs S.D. Brock H.W. et al.MLL targets SET domain methyltransferase activity to Hox gene promoters.Mol Cell. 2002; 10: 1107-1117Abstract Full Text Full Text PDF PubMed Scopus (583) Google Scholar, 72Guenther M.G. Jenner R.G. Chevalier B. et al.Global and Hox-specific roles for the MLL1 methyltransferase.Proc Natl Acad Sci U S A. 2005; 102: 8603-8608Crossref PubMed Scopus (202) Google Scholar, 73Hughes C.M. Rozenblatt-Rosen O. Milne T.A. et al.Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus.Mol Cell. 2004; 13: 587-597Abstract Full Text Full Text PDF PubMed Scopus (343) Google Scholar, 74Yokoyama A. Somervaille T.C. Smith K.S. Rozenblatt-Rosen O. Meyerson M. Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.Cell. 2005; 123: 207-218Abstract Full Text Full Text PDF PubMed Scopus (190) Google Scholar, 75Yokoyama A. Wang Z. Wysocka J. et al.Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.Mol Cell Biol. 2004; 24: 5639-5649Crossref PubMed Scopus (386) Google Scholar, 76Borkin D. He S. Miao H. et al.Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo.Cancer Cell. 2015; 27: 589-602Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar]. Unlike the embryonic lethality caused by complete deletion of MLL1, mice that harbor homozygous MLL1 with a SET domain deletion (MLL1ΔSET) survive into adulthood. These mice exhibit skeletal abnormalities with altered Hox gene expression [77Terranova R. Ahherbi H. Boned A. Meresse S. Djabali M. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll.Proc Natl Acad Sci U S A. 2006; 103: 6629-6634Crossref PubMed Scopus (79) Google Scholar]; however, they show normal hematopoiesis into adulthood [78Mishra B.P. Zaffuto K.M. Artinger E.L. et al.The histone methyltransferase activity of MLL1 is dispensable for hematopoiesis and leukemogenesis.Cell Rep. 2014; 7: 1239-1247Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar]. Intriguingly, the profile of H3K4 methylation at Hoxa loci remains normal in hematopoietic stem/progenitor cells isolated from MLL1ΔSET mice, suggesting that either the SET domain activity of MLL1 is compensated for by other SET domain-containing histone H3K4 methyltransferases in the hematopoietic system or MLL1 is not the dominant H3K4 methyltransferase that controls Hox gene expression. Numerous examples of dysregulated HOX gene expression are found to drive tumorigenesis [79Shah N. Sukumar S. The Hox genes and their roles in oncogenesis.Nat Rev Cancer. 2010; 10: 361-371Crossref PubMed Scopus (194) Google Scholar]. Because MLL1 is a critical regulator of HOX genes in hematopoietic tissue, it is believed that the aberrant expression of HOXA genes in MLL1-rearranged leukemias is attributable to the targeting of chimeric MLL1 fusion proteins to these loci [61Milne T.A. Martin M.E. Brock H.W. Stany R.K. Hess J.L. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.Cancer Res. 2005; 65: 11367-11374Crossref PubMed Scopus (89) Google Scholar]. In fact, the genomic loci directly bound by a MLL1-fusion protein (MLL–AF9) were defined in a mouse AML model using chromatin immunoprecipitation and high-throughput sequencing [80Bernt K.M. Zhu N. Sinha A.U. et al.MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.Cancer Cell. 2011; 20: 66-78
Referência(s)